GLPBio

Apoptosis

Read More about this category

As one of the cellular death mechanisms, apoptosis, also known as programmed cell death, can be defined as the process of a proper death of any cell under certain or necessary conditions. Apoptosis is controlled by the interactions between several molecules and responsible for the elimination of unwanted cells from the body.

Many biochemical events and a series of morphological changes occur at the early stage and increasingly continue till the end of apoptosis process. Morphological event cascade including cytoplasmic filament aggregation, nuclear condensation, cellular fragmentation, and plasma membrane blebbing finally results in the formation of apoptotic bodies. Several biochemical changes such as protein modifications/degradations, DNA and chromatin deteriorations, and synthesis of cell surface markers form morphological process during apoptosis.

Apoptosis can be stimulated by two different pathways: (1) intrinsic pathway (or mitochondria pathway) that mainly occurs via release of cytochrome c from the mitochondria and (2) extrinsic pathway when Fas death receptor is activated by a signal coming from the outside of the cell.

Different gene families such as caspases, inhibitor of apoptosis proteins, B cell lymphoma (Bcl)-2 family, tumor necrosis factor (TNF) receptor gene superfamily, or p53 gene are involved and/or collaborate in the process of apoptosis.

Caspase family comprises conserved cysteine aspartic-specific proteases, and members of caspase family are considerably crucial in the regulation of apoptosis. There are 14 different caspases in mammals, and they are basically classified as the initiators including caspase-2, -8, -9, and -10; and the effectors including caspase-3, -6, -7, and -14; and also the cytokine activators including caspase-1, -4, -5, -11, -12, and -13. In vertebrates, caspase-dependent apoptosis occurs through two main interconnected pathways which are intrinsic and extrinsic pathways. The intrinsic or mitochondrial apoptosis pathway can be activated through various cellular stresses that lead to cytochrome c release from the mitochondria and the formation of the apoptosome, comprised of APAF1, cytochrome c, ATP, and caspase-9, resulting in the activation of caspase-9. Active caspase-9 then initiates apoptosis by cleaving and thereby activating executioner caspases. The extrinsic apoptosis pathway is activated through the binding of a ligand to a death receptor, which in turn leads, with the help of the adapter proteins (FADD/TRADD), to recruitment, dimerization, and activation of caspase-8 (or 10). Active caspase-8 (or 10) then either initiates apoptosis directly by cleaving and thereby activating executioner caspase (-3, -6, -7), or activates the intrinsic apoptotic pathway through cleavage of BID to induce efficient cell death. In a heat shock-induced death, caspase-2 induces apoptosis via cleavage of Bid.

Bcl-2 family members are divided into three subfamilies including (i) pro-survival subfamily members (Bcl-2, Bcl-xl, Bcl-W, MCL1, and BFL1/A1), (ii) BH3-only subfamily members (Bad, Bim, Noxa, and Puma9), and (iii) pro-apoptotic mediator subfamily members (Bax and Bak). Following activation of the intrinsic pathway by cellular stress, pro‑apoptotic BCL‑2 homology 3 (BH3)‑only proteins inhibit the anti‑apoptotic proteins Bcl‑2, Bcl-xl, Bcl‑W and MCL1. The subsequent activation and oligomerization of the Bak and Bax result in mitochondrial outer membrane permeabilization (MOMP). This results in the release of cytochrome c and SMAC from the mitochondria. Cytochrome c forms a complex with caspase-9 and APAF1, which leads to the activation of caspase-9. Caspase-9 then activates caspase-3 and caspase-7, resulting in cell death. Inhibition of this process by anti‑apoptotic Bcl‑2 proteins occurs via sequestration of pro‑apoptotic proteins through binding to their BH3 motifs.

One of the most important ways of triggering apoptosis is mediated through death receptors (DRs), which are classified in TNF superfamily. There exist six DRs: DR1 (also called TNFR1); DR2 (also called Fas); DR3, to which VEGI binds; DR4 and DR5, to which TRAIL binds; and DR6, no ligand has yet been identified that binds to DR6. The induction of apoptosis by TNF ligands is initiated by binding to their specific DRs, such as TNFα/TNFR1, FasL /Fas (CD95, DR2), TRAIL (Apo2L)/DR4 (TRAIL-R1) or DR5 (TRAIL-R2). When TNF-α binds to TNFR1, it recruits a protein called TNFR-associated death domain (TRADD) through its death domain (DD). TRADD then recruits a protein called Fas-associated protein with death domain (FADD), which then sequentially activates caspase-8 and caspase-3, and thus apoptosis. Alternatively, TNF-α can activate mitochondria to sequentially release ROS, cytochrome c, and Bax, leading to activation of caspase-9 and caspase-3 and thus apoptosis. Some of the miRNAs can inhibit apoptosis by targeting the death-receptor pathway including miR-21, miR-24, and miR-200c.

p53 has the ability to activate intrinsic and extrinsic pathways of apoptosis by inducing transcription of several proteins like Puma, Bid, Bax, TRAIL-R2, and CD95.

Some inhibitors of apoptosis proteins (IAPs) can inhibit apoptosis indirectly (such as cIAP1/BIRC2, cIAP2/BIRC3) or inhibit caspase directly, such as XIAP/BIRC4 (inhibits caspase-3, -7, -9), and Bruce/BIRC6 (inhibits caspase-3, -6, -7, -8, -9). 

Any alterations or abnormalities occurring in apoptotic processes contribute to development of human diseases and malignancies especially cancer.

 

References:

1.Yağmur Kiraz, Aysun Adan, Melis Kartal Yandim, et al. Major apoptotic mechanisms and genes involved in apoptosis[J]. Tumor Biology, 2016, 37(7):8471.

2.Aggarwal B B, Gupta S C, Kim J H. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey.[J]. Blood, 2012, 119(3):651.

3.Ashkenazi A, Fairbrother W J, Leverson J D, et al. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors[J]. Nature Reviews Drug Discovery, 2017.

4.McIlwain D R, Berger T, Mak T W. Caspase functions in cell death and disease[J]. Cold Spring Harbor perspectives in biology, 2013, 5(4): a008656.

5.Ola M S, Nawaz M, Ahsan H. Role of Bcl-2 family proteins and caspases in the regulation of apoptosis[J]. Molecular and cellular biochemistry, 2011, 351(1-2): 41-58.

Research Areas

Products Related to Apoptosis(3327)

  • GC72985 structure
    GC72985Z-LEVD-FMK
    CAS: 1135688-25-3
    Purity: >98.50%

    Z-LEVD-FMK est un inhibiteur de la caspase - 4 perméable aux cellules.

  • GC72991 structure
    GC72991(Rac)-Lisaftoclax
    CAS: 2651980-10-6
    Purity: >98.00%

    (Rac)-Lisaftoclax RAC - APG - 2575 est un inhibiteur de Bcl - 2 qui peut être utilisé dans l'étude hémato - maligne cn112898295a.

  • GC72994 structure
    GC72994RAPTA-C
    CAS: 372948-28-2
    Purity: >99.00%

    RAPTA-C (Ru (η6 - ène) Cl2 (PTA)) est un agent anticancéreux et anti - angiogénique.

  • GC73002 structure
    GC73002Ganglioside GD3 diammonium
    Purity: >98.00%

    Ganglioside GD3 diammonium est un glycosphingolipide acide.

  • GC73016 structure
    GC73016AZD4877
    CAS: 758722-49-5
    Purity: >98.00%

    AZD4877 est un autre isostère de l’ispinesib et également un inhibiteur de la protéine du fuseau kinesin (Eg5) avec une ci50 de 2 nM.

  • GC73025 structure
    GC73025Teprasiran sodium
    CAS: 2169310-72-7
    Purity: >90.00%

    Teprasiran sodium est un petit ARN interférant qui inhibe temporairement la mort cellulaire médiée par p53, qui est à la base de l'insuffisance rénale aiguë (Aki).

  • GC73077 structure
    GC73077ARI-1
    Purity: >99.00%

    ARI-1 est un inhibiteur du récepteur orphelin récepteur 1 (ror1) de type tyrosine kinase.

  • GC73093 structure
    GC73093Custirsen sodium
    Purity: >98.00%

    Custirsen sodium inhibe la production de clusterin, une protéine anti - apoptotique régulée à la hausse après la chimiothérapie et conférant une résistance au traitement.

  • GC73109 structure
    GC73109Danvatirsen sodium
    Purity: >97.00%

    Danvatirsen sodium est un oligonucléotide antisens ciblant STAT3 avec une activité antitumorale potentielle.

  • GC73112 structure
    GC73112JPS014 TFA
    Purity: >98.00%

    JPS014 TFA est un chimère ciblé protéolytiquement (protac) de la ligase E3 de von Hippel - Lindau (VHL) à base de Benzamide.

  • GC73118 structure
    GC73118EB1
    CAS: 42951-68-8
    Purity: >99.00%

    EB1 est un inhibiteur de la kinase mnk avec une IC50 de 0,69 µm (mnk1) et 9,4 µm (mnk2), respectivement.

  • GC73129 structure
    GC73129SIAIS164018 hydrochloride
    Purity: >99.00%

    SIAIS164018 hydrochloride est un dégradant ALK à base de protac et EGFR, avec une valeur ci50 de 2,5 nM et 6,6 nM pour ALK et ALK G1202R, respectivement.

  • GC73133 structure
    GC73133Misetionamide
    CAS: 856785-75-6
    Purity: >99.00%

    Misetionamide est un composé oral oxythiazine - like.

  • GC73136 structure
    GC73136VPC-70063
    CAS: 13571-44-3
    Purity: >99.00%

    VPC-70063 est un puissant inhibiteur de myc - max avec une IC50 de 8,9 μm inhibant l'activité transcriptionnelle de myc - Max.

  • GC73138 structure
    GC73138PBENZ-DBRMD
    CAS: 1454662-41-9
    Purity: >99.00%

    PBENZ-DBRMD est un puissant inhibiteur de l’iodotronine déiodinase de type 3 (DIO3).

  • GC73146 structure
    GC73146Sonrotoclax
    CAS: 2383086-06-2
    Purity: >99.00%

    Sonrotoclax est un puissant inhibiteur oral actif de Bcl - 2.

  • GC73159 structure
    GC73159KTX-582
    CAS: 2573298-13-0
    Purity: >98.00%

    KTX-582 est un puissant agent de dégradation irak4 avec des valeurs de dc50 de 4 nm pour irak4 et 5 nm pour ikaros.

  • GC73166 structure
    GC73166U7D-1
    Purity: >99.00%

    U7D-1 est un dégradeur PROTAC puissant et sélectif de première classe USP7 (ubiquitin-specific protease 7), avec un DC50 de 33 nM dans les cellules RS4;11.

  • GC73168 structure
    GC73168p53 Activator 3
    CAS: 2636839-90-0
    Purity: >95.00%

    p53 Activator 3 (composé 87A) est un puissant activateur de p53 avec une valeur sc150 < 0,05 mm.

  • GC73188 structure
    GC73188SFI003
    CAS: 2361332-90-1
    Purity: >99.00%

    SFI003 est un inhibiteur de SRSF3 qui entraîne l’apoptose des cellules CRC via l’axe SRSF3/DHCR24/ROS et présente de puissants effets antitumoraux à la fois in vitro et in vivo.

  • GC73199 structure
    GC73199M47
    CAS: 890808-56-7
    Purity: >99.00%

    M47 est une petite molécule qui déstabilise sélectivement le Cryptochrome 1 (CRY1) et augmente la dégradation du CRY1 dans le noyau.

  • GC73210 structure
    GC73210MTR-106
    CAS: 1639357-93-9
    Purity: >99.00%

    MTR-106 est un puissant stabilisateur G - tétrabrinoïde actif par voie orale et un inhibiteur de l'ARN polymérase I.

  • GC73212 structure
    GC73212TH-6
    CAS: 3031349-25-1
    Purity: >95.00%

    TH-6 est un puissant inhibiteur de HDAC avec des IC50 de 0115, 0135, 0242, 0138 et 2120 µm pour HDAC1, HDAC2, hdac3, hdac6 et hdac8, respectivement.

  • GC73220 structure
    GC73220LSD1-IN-24
    CAS: 4734-59-2
    Purity: >99.00%

    LSD1-IN-24(composé 3S) est un inhibiteur sélectif de LSD1 avec ci50 = 0,247 μM.